Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03639324
Title Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL (RIVe-CLL)
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors Virginia Commonwealth University

chronic lymphocytic leukemia


Idelalisib + Rituximab + Venetoclax

Age Groups: adult | senior
Covered Countries

No variant requirements are available.